The concept of a cure in oncology, particularly for stage II and III colon cancer (CC), has historically suffered from ...
“ur finding enables the safe discontinuation of follow-up after 6 years, leading to an improvement in quality of life and a reduction in health care system costs,” study researchers wrote.
Tanya Persaud, who's based in the GTA, reflects on her journey with cancer, getting a mastectomy and breast reconstruction.
With health care access declining, many turn to social media for health advice. But what happens when that advice is misleading or dangerous?
Has a wellness influencer ever told you something that's too good to be true? According to research and experts, this is becoming increasingly common.
(NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA ® (tucatinib) in patients with ...
I haven't had a consistent primary care doctor since I turned 18 and moved on from the pediatrician I'd seen since birth.
Enhertu Benefit in HER2-Low Breast Cancer That's Also HR-Negative Supported by Longer Follow-Up Data
Like with HR-positive patients, researchers found that patients with HR-negative or ER-low tumors lived longer on Enhertu than chemo after nearly three years.
Pareti completed eight cycles of chemotherapy, four before surgery and four after. Today, she proudly calls herself a cancer ...
Bristol Myers Squibb to Present Data at ESMO® 2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback